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Abstract
Background: The overexpression of sodium-glucose cotransporter 2 (SGLT2) in diabetic kidneys has been reported.
It has also been established that the diabetic glomerular endothelium expresses the toll-like receptors TLR2 and
TLR4. The present study aims to examine the renal SGLT2 induction by the TLR2/4 ligand Porphyromonas (P.)
gingivalis lipopolysaccharide (Pg-LPS) in mouse diabetic nephropathy.
Methods: Immunohistochemical study and tissue RT-PCR analyses were performed on mouse kidneys in
streptozotocin (STZ)-induced diabetic ICR mice (STZ-ICR), in healthy ICR mice administered Pg-LPS (LPS-ICR), and in
diabetic ICR mouse kidneys with Pg-LPS-induced nephropathy (LPS-STZ).
Results: In the quantitative analysis of blood sugar levels, the mean time to reach 600 mg/dl was shorter in the
LPS-STZ than in the STZ-ICR kidneys. The rise in blood glucose levels was significantly steeper in the LPS-STZ than
in the STZ-ICR kidneys. According to these data the LPS-STZ model suggests a marked glucose intolerance. The
expression of SGLT2 was significantly stronger in the whole of the renal parenchyma of the LPS-STZ than in the
LPS-ICR or in the STZ-ICR. The expression of SGLT2 was observed both in the renal tubules and around the renal
tubules, and in the glomeruli of the LPS-STZ kidneys. In the analysis by tissue real-time PCR and cell ELISA, the
expression of the SGLT2 gene and protein was significantly stronger in the LPS-STZ than in the LPS-ICR or in the
STZ-ICR. There were no differences in the renal SGLT2 production in the LPS-ICR and the STZ-ICR kidneys.
Conclusions: Abnormally high renal expression of SGLT2 occurs in diabetic kidneys with P. gingivalis LPS.
Periodontitis may be an exacerbating factor in diabetic nephropathy as well as in diabetes.
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Background
The pathological mechanisms which cause individual
differences in the progression of diabetes and in the ac-
companying complications are not fully elucidated. Dia-
betic glomerulosclerosis exhibits characteristics such as:
diffuse lesions due to increased mesangial matrix includ-
ing type I collagen by the production of several different
cytokines through the recognition of advanced glycation
end products (AGE) in a hyperglycemic environment
[1]; nodular lesions with circular enlargement of the
mesangial region as Kimmelstiel-Wilson nodules; exuda-
tive lesions with a fibrin cap in which plasma compo-
nents are stored in the hemispheric space between
glomerular tuft endothelial cells and the basement mem-
brane and in a capsular drop filled with plasma compo-
nents stored between the Bowman’s epithelium and the
basement membrane [2]. It has been shown that hyper-
glycemia induces the TLR2/4 expression via PKC-α/δ
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with NADPH oxidase activation in leukocytes [3, 4]. The
metabolic recognition of AGE by the renal toll-like re-
ceptor (TLR) like the AGE receptor has been suggested
as one candidate for the occurrence of diabetic nephrop-
athy [5–7]. The TLR recognizes pathogen-associated
molecular patterns like lipopolysaccharide (LPS) in
microorganism components, and elevated levels of
TLR2/4 expression have been reported in leukocytes in
diabetic patients [8–12]. The renal TLR ligand binding
induces the production of inflammatory cytokines which
activate inflammatory events in kidneys [13–17]. The
periodontal pathogen Porphyromonas (P.) gingivalis LPS
(Pg-LPS) induces the production of inflammatory agents
by host defense systems recognizing lipid A and co-
existing molecules of TLR2 and TLR4 [18–20]. The Pg-
LPS acts as a periodontal pathogen leading to periodon-
tal tissue destruction and is also a risk factor in cardio-
vascular disorders [21, 22]. It is thought that patients
with severe periodontitis are liable to cause bacteremia
of the systemic circulation with oral microorganisms,
resulting in the renal accumulation of bacterial compo-
nents or the immune complexes like in IgA nephropathy
[23–25]. Intestinal microorganisms also enter the circu-
lation but are directly sterilized in the liver while oral
microorganisms enter the systemic circulation directly;
this has led to the suggestion that head and neck infec-
tions spread throughout the body and enter the kidney
via the systemic circulation [24–27].
We recently reported that the glomerular endothelium
expresses TLR2 and TLR4 in streptozotocin (STZ)-in-
duced diabetic mice [28], and that all Pg-LPS-
administered diabetic mice reached humane endpoints
within the survival time of all diabetic mice and Pg-LPS-
administered non-diabetic mice [29]. The diabetic mice
administered Pg-LPS showed nephropathy with glomer-
ulosclerosis based on the glomerular accumulation of
type 1 collagen and inflammatory cytokines. The Pg-LPS
administrated diabetic mice showed high levels of sugar/
protein in the urine and blood urea nitrogen (BUN)/cre-
atinine (CRE). The progress of these effects was sup-
pressed by the administration of the TLR4 inhibitor
Eritoran [30]. This has led to suggestion that periodon-
titis may be a risk factor in exacerbating nephropathy in
diabetic patients [28–30]. It has been reported that there
is overexpression of sodium-glucose cotransporter 2
(SGLT2) in diabetic kidneys [31–33]. The SGLT actively
transport glucose with the sodium transport across the
intestinal epithelial cells and the proximal renal tubule
epithelial cells against the concentration gradient. Ap-
proximately 90% of the filtered renal glucose is reab-
sorbed at the early convoluted segment of the proximal
tubule by SGLT2. The glucose transported into proximal
tubular cells exits the basolateral cell border and are
returned to the circulation [32, 33]. Recently, SGLT2
inhibitors are used to suppress diabetic nephropathy
[32–34], however, the mechanisms that cause the abnor-
mal expression of SGLT2 are still not fully elucidated.
With the increased expression of SGLT2 in diabetic pa-
tients, SGLT2 has been suggested as an important factor
in exacerbating diabetes in a production amount-
dependent manner. The mechanism of the increase in
the renal glucose reabsorption for hyperglycemia in-
volves the overexpression of glucose transporter genes in
the proximal tubule [31–33]. In both rodent diabetic
models [35–37] and humans [31] the upregulation of
SGLT2 gene/protein has been reported in the renal
proximal tubular cells. In cultured proximal tubular cells
isolated from type II diabetic patients and healthy con-
trols SGLT2 and GLUT2 mRNA levels and glucose
transport are significantly higher in the diabetes group
[31], and diabetic rodent models show similar results. It
has been thought that increased plasma glucose ultim-
ately leads to increased SGLT2 and GLUT2 mRNA/pro-
tein expression in the renal proximal tubular cells [32,
33]. Considering the possibility of periodontitis as a risk
factor for exacerbating nephropathy, it may be postu-
lated that the SGLT2 overexpression could be provoked
by P. gingivalis in diabetic kidneys. The present study
aims to examine the expression of SGLT2 in mouse kid-
neys with Pg-LPS-induced diabetic nephropathy.
Methods
Animals
All processes for the upkeep of animals and experiments
were conducted in the Fukuoka Dental College Animal
Center following the conditions and procedures de-
scribed elsewhere [30]. This study was conducted to in-
vestigate the SGLT2 expression in the Pg-LPS-induced
diabetic nephropathy model mice. The protocol of the
animal investigation was approved by the Animal Ex-
periment Committee of Fukuoka Dental College (No.
19010). The 4-week-old male mice of the ICR closed line
were purchased from a commercial vendor (Kyudo, Fu-
kuoka, Japan). The animal number was decided accord-
ing to rules by the Animal Experiment Committee of
Fukuoka Dental College based on the appropriate num-
ber of animals in biomedical research from the view-
point of animal welfare [38]. In the case of genetically
identical animal groups of the same lineage, 5 or more
animals per group, and the test using 4 groups including
the control group, are considered appropriate. This
study used 4 groups (8 mice in each group): non-treated
control (data not shown), LPS-administered non-
diabetic control, diabetic control, and Pg-LPS-
administered diabetic experimental. All specimens were
collected from euthanized mice according to the AR-
RIVE guidelines. The humane endpoints were assessed
daily and mice reaching humane endpoints were
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euthanized by induction anesthesia with intraperitoneal
injections of sodium pentobarbital and cervical disloca-
tion. In this study, data for all the mice were included in
the experimental and control data, and there were no
exclusions. Recently, we have established the Pg-LPS-
injected diabetic nephropathy mouse model as described
elsewhere [30]. Briefly, a single intraperitoneal injection
of STZ (Sigma-Aldrich Japan, Tokyo, Japan) was admin-
istrated to mice under inhalation anesthesia and blood
glucose concentrations were checked by a Glutest Sen-
sor (Sanwa Kagaku Kenkyusyo CO., LTD., Nagoya,
Japan) twice a week after the injection. The STZ-
injected ICR mice with blood glucose levels of over 600
mg/dl were assigned as STZ-induced diabetic mice
(STZ-ICR). After the single STZ injection of Pg-LPS of
3 mg/kg (LD50 = 30mg/kg body weight; Invivogen, San
Diego, California, USA) which have been confirmed to
have no effect on the health condition in healthy ICR
mice in our previous study was further injected with
STZ-ICR just below the buccal mucosa, once a week for
4 months under inhalation anesthesia [30]. The mice
were monitored for sugar, protein, and bleeding in the
urine by urine reagent strips (Uriace, Terumo Corpor-
ation, Tokyo, Japan); blood which was collected from
the tail vein under anesthesia was analyzed for blood
urea nitrogen (BUN) and creatinine (CRE) by Kyudo
Co., LTD (Tosu, Japan). When the mice showed strongly
positive levels of sugar and protein in the urine by the
reagent strips (Uriace, Terumo), and simultaneously
showed BUN levels of above 40 mg/dl and CRE levels of
above 0.7 mg/dl (Kyudo, Tosu, Japan), they were
assigned as STZ and Pg-LPS-induced diabetic nephropa-
thy mice according to our previous study [29, 30]. In
summary, we performed this study using 32 ICR mice
divided into four groups (n = 8 per group) which is the
smallest number that makes it possible to achieve statis-
tically reliable results: the healthy control ICR mice
without any treatment (data not shown), control ICR
mice treated with Pg-LPS (the experimental infection
model, LPS-ICR), control ICR mice treated with STZ
(the experimental diabetes model, STZ-ICR), and ICR
mice treated with Pg-LPS and STZ (the experimental
diabetic nephropathy model, LPS-STZ). At the end of
the designated period of the experiments, all mice were
euthanized, and tissue was collected.
Immunohistochemistry
The immunohistochemical investigation was performed
by the method described elsewhere [30]. Briefly, frozen
mouse kidney tissue sections were fixed in 100% metha-
nol and treated with primary antibodies (1 μg/ml): ham-
ster monoclonal anti-mouse podoplanin clone 8.8.1
(#127402, BioLegend Inc., San Diego, CA, USA) to dis-
criminate glomeruli and rabbit polyclonal anti-mouse
SGLT2 (#ab85626, Abcam plc., Cambridge, UK), and
rabbit polyclonal anti-type 1 collagen (#ab34710,
Abcam). After the treatment sections were exposed to
secondary antibodies (0.5 μg/ml): Alexa Fluor 488 and
568-conjugated goat anti-hamster and anti-rabbit IgGs
(Probes Invitrogen Com., Eugene, OR, USA). Cell nuclei
were counterstained with 4′, 6-diamidino-2-phenylin-
dole (DAPI). The immunostained sections were exam-
ined by microscope digital camera systems with a CFI
Plan Apo Lambda lens series and DS-Ri2/Qi2 (Nikon
Corp., Tokyo, Japan). All experiments were replicated
several times (5–10) with different sections. The immu-
nostained sections used in the Figures were consecu-
tively stained by haematoxylin and eosin (HE) to identify
the immunostained regions.
Real-time PCR
The analysis was as described elsewhere [30]. Immedi-
ately after excision 5 mm squares of tissue from mouse
kidneys were ground into a paste with a scalpel on glass
plates on ice and dissolved in the RLT buffer of an
RNeasy kit (Qiagen, Inc., Tokyo, Japan). The total RNA
extraction from the tissue was performed with a QIAsh-
redder column and an RNeasy kit (Qiagen). When many
non-specific bands were identified at the gel electro-
phoresis after the PCR, a DNAfree kit (Ambion, Hun-
tingdon, UK) was used to remove contaminating
genomic DNA. After the total RNA extraction, reverse
transcription was performed on 30 ng of total RNA,
followed by 38 cycles (annealing: 60 °C) of PCR for amp-
lification using the Ex Taq hot start version (Takara Bio
Inc., Otsu, Japan) with 50 pM of primer sets for SGLT2
mRNA (forward: CCCATCCCTCAGAAGCATCTCC;
reverse: CTCATCCCACAGAACCAAAGCA) where the
specificities had been confirmed by the manufacturer
(Sigma-Aldrich Japan, Tokyo, Japan). The cDNA sam-
ples were also analyzed by real-time quantitative PCR to
quantify the mRNA amounts. The cDNA (1 μl) was
amplified in a 25-μl volume of PowerSYBR Green PCR
Master Mix (Applied Biosystems, Foster City, CA, USA)
in a Stratagene Mx3000P real-time PCR system (Agilent
Technologies, Inc., Santa Clara, CA, USA) and the fluor-
escence was monitored at each cycle. Cycle parameters
were 95 °C for 15 min to activate Taq followed by 40 cy-
cles of 95 °C for 15 s, 58 °C for 1 min, and 72 °C for 1
min. Two standard curves were created for the real-time
analysis from amplicons for β-actin and target genes in
three serial 4-fold dilutions of cDNA. The β-actin/target
gene cDNA levels in each of the sample were quantified
against β-actin/target gene standard curves by allowing
the Mx3000P software to accurately determine each
cDNA units. Finally, the target gene cDNA amounts in
each sample were normalized to β-actin cDNA. Relative
amounts for the target gene expression were expressed
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as arbitrary units, calculated according to the following
formula: relative experimental gene expression units =
STZ-ICR or LPS-STZ cDNA amounts/LPS-ICR cDNA
amounts. All experiments were repeated at least five
times.
Tissue ELISA
The analysis was performed by modifying the cell ELISA
for tissue, and is as described elsewhere [30]. Normal
mouse 5 mm square tissue of kidneys were collected
after euthanasia by induction anesthesia of the mice with
2% isoflurane (1 l/min) and intraperitoneal injections
with sodium pentobarbital (10 ml/kg, Nembutal, Abbott
Laboratories, North Chicago, IL). Immediately after exci-
sion of the tissue, cryo-embedding in Tissue-Tek Cryo-
mold (Sakura Finetek Japan Co., Ltd., Tokyo, Japan) was
performed using liquid nitrogen. Frozen 10 μm sections
cut in a cryostat on the slide glass were fixed in 100%
methanol for 5 min at − 20 °C. The sections were treated
with PBS blocking solution containing 0.1% goat serum
for 30 min at 20 °C and then with a drop of blocking so-
lution (0.2 ml) containing 1 μg/ml rabbit anti-mouse
SGLT2 (Abcam) or rabbit anti-mouse β-actin (#8226,
Abcam) for 8 h at 4 °C. After the primary antibody treat-
ment, the sections were washed three times in PBS for
10 min and treated with a drop of blocking solution (vol-
ume 0.2 ml) containing peroxidase-conjugated second
antibodies (0.1 μg/ml) for 1 h at 20 °C, and then visual-
ized by a drop of ABTS peroxidase substrate solution
(0.2 ml, SeraCare Life Sciences, Inc.) at room
temperature. A 0.15 ml volume of the reaction products
were added to the wells of a 96-well microplate and ab-
sorbance changes at 405 nm were measured by a micro-
plate reader. Tissue sections treated with only a second
antibody served as blanks. The produced amounts of
SGLT2 protein were expressed as the mean absorbance
of peroxidase metabolizing substrate of six sections and
normalized to the absorbance of reaction products with
rabbit anti-mouse β-actin (Abcam). Relative production
amounts were expressed as arbitrary units according to
the formula: STZ-ICR or LPS-STZ absorbance / LPS-
ICR absorbance.
Statistics
Animal experiments were performed with 32 mice in 4
groups (8 mice in each group) as described above. All
experiments for immunohistochemistry, RT-PCR and
ELISA were repeated five times. Data were expressed as
the mean + SD and mean values were calculated with
standard deviations. The statistical significance of the
differences (P < 0.01) was determined by one-way
ANOVA and two-tailed unpaired Student’s t test with
STATVIEW 4.51 software (Abacus concepts, Calabasas,
CA, USA). The corresponding author was fully aware of
the group allocation at the different stages of the experi-
ments. The data analysis and assessments were per-
formed by all co-authors.
Results
Quantitative analysis of blood sugar levels, and SGLT
mRNA and protein
The time to reach the blood glucose level of 600 mg/dl
was shorter in the Pg-LPS-administered diabetic mice,
the LPS-STZ, than in the diabetic mice without Pg-LPS,
the STZ-ICR, and the slope of the rise in blood glucose
levels was significantly steeper in the LPS-STZ than in
the STZ-ICR specimens (Fig. 1A). The real time-PCR
analysis shows that the renal gene expression of SGLT2
was significantly stronger in LPS-STZ than in the Pg-
LPS-administered non-diabetic ICR mice, the LPS-ICR,
and the STZ-ICR mice. There were no significant differ-
ences in the renal gene expression of SGLT2 between
LPS-ICR and STZ-ICR. The tissue ELISA analysis
showed that the renal production of SGLT2 protein was
significantly larger in the LPS-STZ than in the LPS-ICR
and STZ-ICR. There were no differences in the renal
production of SGLT2 protein of the LPS-ICR and STZ-
ICR (Fig. 1B).
Immunostaining of type I collagen and SGLT2
Reaction products of anti-type I collagen were identified
weakly in the ICR (not shown), LPS-ICR, and STZ-ICR
specimens and strongly in the whole of the renal paren-
chyma and in the glomeruli of the LPS-STZ specimens
(Fig. 2). There was rarely any type I collagen accumula-
tion by administration of only Pg-LPS or STZ, but it was
commonly detected in the glomerular mesangial and
tubulointerstitial accumulation by Pg-LPS in the diabetic
mice. Reaction products of anti-SGLT2 were weakly
identified in the ICR (not shown), LPS-ICR, and STZ-
ICR specimens, whereas reaction products were strongly
identified in the LPS-STZ specimens in the renal prox-
imal tubular lumen as well as at the outer wall of the tu-
bules (Fig. 3). In the high magnification, reaction
products of anti-type I collagen were observed around
the renal tubules and in the glomeruli, and in the renal
columns of LPS-STZ (Fig. 4). Reaction products of anti-
SGLT2 were detected in only the renal proximal tubules
of STZ-ICR whereas the reaction products were detected
both in the renal tubules as well as at the outer wall of
LPS-STZ (Fig. 4). There was leukocyte accumulation,
like inflammatory leukocyte infiltration, in the glomeruli
of LPS-STZ (Fig. 4). The leukocyte accumulation was
observed in the juxtaglomerular apparatus of the vascu-
lar pole. In the high magnification of LPS-STZ there
were strong reaction products with anti-SGLT2 detected
both in the renal proximal tubular lumen and at the
outer wall of the tubules, especially strongly at the
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tubular wall around blood vessels (Fig. 5). Leukocyte ac-
cumulation including podoplanin-positive macrophages
was also observed around vessels in the renal paren-
chyma (Fig. 5).
Discussion
Glomerulosclerosis is well-known as a serious complica-
tion which causes diabetic nephropathy in diabetes mel-
litus. We have recently reported that Pg-LPS exacerbates
mouse diabetic nephropathy, and that diabetic nephro-
pathic mice show glomerulosclerosis with the renal ac-
cumulation of type 1 collagen [28–30]. Therefore, this
study used the immunostaining of type I collagen accu-
mulation as an indicator for glomerulosclerosis. The
mean time to reach 600 mg/dl was shorter in mice which
had LPS-STZ with Pg-LPS administered repeatedly after
a single STZ injection than in STZ-ICR mice which were
only administered STZ, and the increase in blood glu-
cose levels was significantly more rapid in LPS-STZ than
in STZ-ICR (Fig. 1A). According to these data the LPS-
STZ model suggests a marked glucose intolerance and it
is thought that Pg-LPS induces both diabetic nephropa-
thy as well as the diabetes. It was confirmed that the
SGLT2 gene and protein expression amounts were sig-
nificantly stronger in LPS-STZ than in LPS-ICR and in
STZ-ICR (Fig. 1B), and there were no differences in the
SGLT2 production of LPS-ICR and STZ-ICR, suggesting
that P. gingivalis infection is the cause of the renal over-
expression of SGLT2 under diabetic conditions, and that
the SGLT2 overexpression does not occur only with one
of diabetes or Pg-LPS. Since the glucose reabsorption by
the overexpressed SGLT2 in the renal tubules is thought
to be an important factor in exacerbating diabetes [31–
33], these observations would allow the conclusion that
periodontitis may be a critical factor in the progress of
diabetes. The amounts of accumulated type I collagen in
the whole of the renal parenchyma and in the glomeruli
were much larger in LPS-STZ than in the kidneys of
ICR (not shown), STZ-ICR, and LPS-ICR (Fig. 2). It was
shown that collagen accumulation rarely occurs by only
Fig. 1 Quantitative analysis of blood sugar levels, and SGLT2 mRNA and protein of diabetic mice with Pg-LPS. (A) Quantitative analysis of blood
sugar levels. The mean time to reach 600mg/dl (n = 8) was shorter in LPS-STZ than in STZ-ICR. The increase in blood glucose levels was
significantly steeper in LPS-STZ than in STZ-ICR. (B) RT-PCR and tissue ELISA analysis of renal SGLT2. Real time-PCR analysis shows that the
amounts of gene expression of SGLT2 were significantly larger in LPS-STZ than in LPS-ICR (LPS) and STZ-ICR (STZ). There was no difference
between the amounts of LPS-ICR and STZ-ICR. The cDNA amounts are normalized to the β-actin cDNA amounts. Relative gene expression
amounts are expressed as arbitrary units: cDNA from STZ-ICR and LPS-STZ/cDNA from LPS. Values are mean ± SD. * Significantly different in
ANOVA (P < 0.01). The tissue ELISA analysis of the mouse kidney sections shows that the protein production of SGLT2 was significantly larger in
LPS-STZ than in LPS-ICR (LPS) and in STZ-ICR (STZ). There was no difference between the LPS and STZ amounts. The protein amounts were
expressed as the mean absorbance of peroxidase metabolizing substrate of six sections and the absorbance was normalized to the absorbance
with anti-β-actin. Relative produced amounts of gene/protein are expressed as arbitrary units: absorbance of STZ or LPS-STZ/absorbance of LPS.
Values are mean ± SD. *Significantly different in ANOVA (P < 0.01)
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Fig. 2 Immunostaining of type I collagen in diabetic mouse kidneys with Pg-LPS. HE staining (left column); immunostaining for type I collagen
(red) (center column); and merged immunostaining for type I collagen and podoplanin (green) (right column), with DAPI staining of nuclei (blue).
The glomerular epithelial cells were immunostained by anti-podoplanin to discriminate glomeruli (yellow arrows). Reaction with anti-type I
collagen was weakly identified in LPS-ICR (top row) and in STZ-ICR (middle row) while the reaction was identified in the whole renal parenchyma
(arrowheads) and in glomeruli (arrows) in LPS-STZ (bottom row). Bars: 100 μm
Fig. 3 Immunostaining of SGLT2 in diabetic mouse kidneys with Pg-LPS. HE staining (left column); immunostaining for SGLT2 (red) (center
column); and merged immunostaining for SGLT2 and podoplanin (green) (right column), with DAPI staining of nuclei (blue). The glomerular
epithelial cells were immunostained by anti-podoplanin to be able to discriminate glomeruli (yellow arrows). Reaction with anti-SGLT2 was
weakly identified in LPS-ICR (top row) and in STZ-ICR (middle row); the reaction was identified both in the proximal tubular lumen (arrowheads)
and outer wall (arrows) in LPS-STZ (bottom row). Bars: 100 μm
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Pg-LPS or STZ administration but is strong in the glom-
erular mesangial and tubulointerstitial accumulation by
Pg-LPS in diabetic mice (Fig. 2). In the high magnifica-
tion of LPS-STZ the accumulation of type I collagen is
shown to be around the renal tubules and in glomeruli,
as well as in the renal columns (Fig. 4), suggesting that
the kidneys of LPS-STZ became glomerulosclerotic with
the high blood CRE and BUN levels described above.
In this study the expression of SGLT2 was much
stronger throughout the renal parenchyma of the LPS-
Fig. 4 High magnification of immunostained type I collagen and SGLT2 in diabetic mouse glomeruli with Pg-LPS. HE staining (left column);
immunostaining for type I collagen/SGLT2 (red) (center column); and merged immunostaining for type I collagen/SGLT2 and podoplanin (green)
(right column), with DAPI staining of nuclei (blue). In LPS-STZ (top row) a strong reaction with anti-type I collagen was observed around the renal
tubules, in glomeruli (arrows), and in renal columns (asterisks). In STZ-ICR (middle row) reaction to anti-SGLT2 was identified only in the proximal
tubular lumen (arrowheads). In LPS-STZ (bottom row) strong reaction with anti-SGLT2 was observed at the brush border side in the renal
proximal tubules (arrowheads) as well as at the outer wall of the tubules (arrows). There was a cell accumulation like leukocyte infiltration in the
glomeruli (yellow arrows). Bars: 100 μm
Fig. 5 Immunostaining of SGLT2 in diabetic mouse renal vessels with Pg-LPS. HE staining (left column); immunostaining for SGLT2 (red) (center
column); and merged immunostaining for SGLT2 and podoplanin (green) (right column), with DAPI staining of nuclei (blue) of LPS-STZ. In the
immunostaining around a blood vessel (top row) reaction with anti-SGLT2 was observed significantly at the blood vessel side of proximal tubule
outer walls (white arrows) and in the tubular lumen (arrowheads). Podoplanin-positive macrophage-like cells (yellow arrow) were observed
around blood vessels. In the immunostaining of a blood vessel (bottom row) there is a leukocyte accumulation like leukocyte infiltration
including podoplanin-positive macrophages (yellow arrows). A significant volume of reactions with anti-SGLT2 is observed at the blood vessel
side of the proximal tubule outer walls (white arrows) and in the tubular lumen (arrowheads). Bars: 100 μm
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STZ than in kidneys of ICR (not shown), STZ-ICR, and
LPS-ICR (Fig. 3). It was shown that the Pg-LPS adminis-
tration induces the SGLT2 overexpression in diabetic
mice but not in healthy mice (Fig. 3). In the high magni-
fication of immunoreaction products, the SGLT2 expres-
sion was observed in the renal proximal tubular lumen
of STZ-ICR (Fig. 4). Only the proximal tubular lumen
was clearly stained in the diabetic mouse kidney while
not only the proximal tubular lumen but also the outer
walls were stained in the Pg-LPS-administered diabetic
mice (Fig. 4). It has been established that the SGLT2 ex-
pression in healthy kidneys occurs only at the brush
border in renal proximal tubule epithelial cells and the
immunohistochemical analysis here was successfully
shown in STZ-ICR (Fig. 4) [31–33]. However, in LPS-
STZ, the overexpression of SGLT2 was observed not
only in the proximal tubular lumen in which the secre-
tion at the brush border is speculated to occur at the
brush border side as well as at the outer wall of the tu-
bules (Figs. 3, 4). Since there were several leukocyte ac-
cumulations resembling an inflammatory infiltration of
leukocytes from glomeruli and vessels in LPS-STZ
(Figs. 4, 5), it is thought that inflammatory overexpres-
sion of SGLT2 occurs in the renal proximal tubules with
Pg-LPS. With the increased expression of SGLT2 in dia-
betic patients, SGLT2 has been suggested as an import-
ant factor in exacerbating diabetes in a production
amount-dependent manner [31–33]. Considering the
possibility of periodontitis as a risk factor in exacerbat-
ing nephropathy in our previous studies [28–30], it may
be postulated that the overexpressed SGLT2 in the renal
proximal tubular epithelial cells by the inflammatory re-
sponse with P. gingivalis in diabetic kidneys increase the
glucose reabsorption.
Commonly occurring intestinal inhabitants like E. coli
could also be present. Such intestinal microorganisms
and the LPS enter the liver via the enterohepatic circula-
tion and are immediately sterilized, however, oral bac-
teria enter the systemic circulation directly without
detoxification. This is the anatomical reason why head
and neck infections spread to the whole body and reac-
tion products accumulate in the kidneys [21–27]. We re-
cently reported that the glomerular endothelium
expresses TLR2/4 in diabetic mice, and that the TLR2/4-
ligand P. gingivalis LPS is a cause of glomerulosclerosis
in diabetic mice with the accumulation of type 1 colla-
gen and inflammatory cytokines in the glomeruli [28–
30]. As nephritis progresses, the SGLT2 accumulates
without being metabolized due to renal dysfunction and
proinflammatory cytokines like IL-6 and TNF-α induce
SGLT2 expression in diabetic kidneys [39–41]. Since the
expression of SGLT2 is increased in diabetic patients
with persistent hyperglycemia and in patients with dia-
betic nephropathy, it is thought that renal glucose
reabsorption by SGLT2 is a serious factor in exacerbat-
ing diabetes and that SGLT2 inhibitors are useful to pre-
vent the development of diabetes complications [31–34].
It may be postulated that under diabetic conditions renal
inflammatory events to P. gingivalis like the TLR recog-
nition induce the production of inflammatory cytokines
and progressively accelerate the abnormal expression of
SGLT2 in glomeruli, renal proximal tubules, intertubular
spaces of the renal parenchyma, and in the peritubular
capillaries. Altogether this could suggest that the peri-
odontal pathogen Pg-LPS causes the nephropathy in dia-
betic patients via TLR expressed by glomerular vascular
endothelial cells. Further, the production of inflamma-
tory cytokines by Pg-LPS may increase the SGLT2 ex-
pression in renal tubules and exacerbate diabetes.
Conclusions
The results here suggest that renal inflammatory events
by P. gingivalis like TLR recognition induce the produc-
tion of inflammatory cytokines and progressively accel-
erate the inflammatory overexpression of SGLT2 in the
renal proximal tubules under diabetic conditions. Our
results suggest that periodontitis could be an exacerbat-
ing factor in both diabetic nephropathy as well as in
diabetes.
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